The COVID-19 pandemic caused by severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) is a global health emergency. An attractive drug target for this coronavirus is the main protease (3C-like proteinase, 3CL^pro, M^pro) because of its essential role in processing the polyproteins that are translated from the viral RNA.

Catechol O‑Methyl Transferase (COMT, HEL-S-98n) degrades catecholamines, catecholestrogens and various drugs having a catechol structure. Mutation of COMT is associated with obsessive-compulsive disorder in men, anxiety phenotypes in women, schizophrenia and other. Developing of the COMT inhibitors is a promising area of neuropsychiatric research. Also catechol‐O‐methyltransferase inhibitors are used as adjuvants to the levodopa/AADC inhibitor therapy for Parkinson's disease treatment.

Enhancer of zeste homolog 2 (EZH2, ENX-1, ENX1, EZH1, EZH2b, KMT6, KMT6A, WVS, WVS2, enhancer of zeste 2 polycomb repressive complex 2 subunit) is a histone-lysine N-methyltransferase. This enzyme plays an important role in histone methylation and, ultimately, transcriptional repression.

Mutation or over-expression of EZH2 has been linked to many forms of cancer, including bladder, uterine, breast, prostate and renal cancers. EZH2 inhibits genes responsible for suppressing of tumor development, and blocking of it activity may slow tumor growth. Therefore, EZH2 is an attractive target for anti-cancer therapy.

Diaryliodonium salts are well-known to transfer an aryl group to carbon and heteroatom nucleophiles, and in some cases a base is required [1]. However, transition metal catalysts and supporting ligands are not needed. Moreover, reactions conducted with diaryliodonium salts are operationally simple because they are non-toxic and are not sensitive to air or moisture. Therefore diaryliodonium salts offer an important alternative to metal-catalyzed arylation reactions. Despite these attractive characteristics, a major obstacle to their adoption in chemical synthesis and discovery chemistry has been commercial availability.

Sphingosine-1-phosphate receptor 1 (S1PR1, S1P receptor 1, S1P1, endothelial differentiation gene 1, EDG1) is a G-protein-coupled receptor which binds the bioactive signaling molecule sphingosine 1-phosphate (S1P). S1PR1 has an important role in regulating endothelial cell cytoskeletal structure, migration, vascular maturation and capillary-like network formation. Also S1PR1 signaling is important in the regulation of lymphocyte maturation, migration and trafficking. Abnormal functioning of S1PR1 is associated with cancer and multiple sclerosis. Agonists and antagonists of this receptor may have therapeutic potential in the treatment of such diseases.

The Retinoic Acid Receptor-related Orphan Receptor-γ (RORγ, RORc, NR1F3, RORG, RZR-GAMMA, RZRG, TOR or IMD42) plays an important role in metabolism, inimmunity and circadian rhythm. Abnormal functioning of RORγ is associated with inflammatory, immune and skin diseases including psoriasis. Antagonists and inverse agonists of this receptor may have therapeutic potential in the treatment of such diseases.

The Matrix metalloproteinase-2 (MMP2, gelatinase A, 72 kDa type IV collagenase) is involved in different functions such as reconstruction of the vasculature, angiogenesis, tissue repair, inflammation, tumor invasion and atherosclerotic plaque rupture. Mutations in the MMP2 gene are associated with Torg-Winchester syndrome, arthritis syndrome, multicentric osteolysis and other pathologies. Therefore, small molecule compounds targeting metalloproteinase-2 may be potential treatment for a variety of diseases related to abnormality functioning of MMP2.

Selective androgen receptor modulators (SARMs) act on the androgen receptors (ARs) in a tissue-selective manner and provide an opportunity to promote the beneficial effects of androgens in target tissues with greatly reduced unwanted side-effects. SARMs have been proposed as treatments of choice for various diseases, including muscle-wasting, breast cancer, and osteoporosis.